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INTRODUCTION
Chloroma (also known as granulocytic sarcoma or 
myeloid sarcoma) is a rare, extramedullary tumor 
composed of immature granulocytic cells. It was first 
described in 1811 and coined “chloroma” by King in 
1853 because of its green color. Its relationship with 
Leukemia was later established in 18933.
Chloromas are reported in 2,5% - 9,1%1,2,3 of pa-
tients with acute myeloid leukemia(AML) and occur 
concomitamtly, following, or rarely antedating the on-
set of leukemia4. The presence of an extramedullary 
relapse of leukemia is often associated with a poor 
prognosis5. The most common locations of chloromas 
are skin, soft tissue, bone, periosteum, and Lymph 
nodes5. Central nervous system (CNS) involvement 
is rare but has been described in numerous case re-
ports6,7,8. Myeloid sarcoma can also develop in leuke-
mia patients concurrently with or after diagnosis,or as 
manifestation of disease relapse15,16. It is rare for the 
clinical manifestation of a myeloid sarcoma to include 
signs of nerve root entrapment. In the current cases we 
present two patients with chloroma who had painful 
mass and edema in soft tissue and lymph nodes.
CASE REPORT
Two patients with chloroma came to our Radiotherapy 
Oncology Department for irradiation. The first patient 
was a 49 year old woman who developed pain and 
edema in her right low foot, 8 months ago. CT (Com-
puter Tomography)revealed involvement by a pre-
sumed chloroma, mass in madibulum, left sacrum, O5 
vertebra and right inguinale nodes (Figure 1). Biopsy 
of the mandibulum indicated myeloid sarcom mixed 
immunophenotyp B/myelogenen type. The patient 
was irradiated palliatively in her right inguinal nodes, 
with a total dose 2000cGy, in 5Fr with 400cGy/Fr 
(Figure 2). At the end of therapy she had decreased 
pain and reduction of edema in her right low foot. The 
CT after two months of irradiation showed reduction 
of mass (presumed chloroma) in her right inguinal 
nodes (Figure 3). There was no recurrence and the 
patient was with improvement and satisfying per-
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formance status. The second patient, was an 70 year 
old woman, came in our radiotherapy department 6 
months ago, with mass on the right neck and supracla-
vicular region. The biopsy proved also myeloid sar-
coma. The patient developed pain and edema in these 
regions.She was irradiated palliatively in the neck and 
the supraclavicular region with dose 2000cGy, in 5Fr 
with 400Gy/Fr. At the end of therapy her mass had 
a significant remission during palpation. She was de-
creased pain and much better improvement. Both of 
them received radiotherapy with three fields, in the 
region of the chloromas and the radiotherapy was the 
treatment planning combined with chemotherapy in 
hematological department.
Figure 1. Involved region(inguinale nodes).
Figure 2. Fields for irradiation(right inguinale nodes).
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DISCUSSION
Chloromas’ rare incidence, their often misdiagno-
sis9 , and variable locations have resulted in limited 
clinical experience, and hence in a lack of consensus 
treatment guidelines. Myeloid sarcoma (chloroma)
is a rare, malignant,and extramedullary solid tumour 
primarily associated with AML (Acute Myelogenous 
Leukemia), especially the M2 subtype, and it is often 
a precursor to the diagnosis of myelogenous leukemia 
or a manifestation of leukemia recurrence. Chloroma 
can also be found in multiple other myelodysplastic 
syndromes and can represent leukemic transforma-
tion2. Of nonleukemic patients who present with my-
eloid sarcoma, most will develop AML within 1 year 
(median 5 months)11. Chloroma has been reported in 
≤9% of patients with AML,most commonly in the 
bone,periosteum, lymph nodes,skin,and multiple soft-
tissue sites2,12. The tumour precedes systemic leuke-
mia in 0,6% of cases 4. Myeloid sarcoma is seen more 
often in men than in women as is generally the case in 
leukemia13. The tumour may appear at any age or lo-
calization. Because of the rarity of this disorder,large 
series of patients are seldom reported,and the progno-
sis and optimal treatment of patients presenting with 
MS are not clear.In general,the prognosis of myeloid 
sarcoma is usually considered to be poor5. Overall,the 
median survival is 7-20 months after the diagnosis of 
chloroma11,14. Considering the diagnosis of myeloid 
sarcoma at an early stage is important because of the 
therapeutic options in this potentially devastating dis-
ease. The role of radiation in their management has 
typically been palliative as low doses have resulted in 
excellent disease control and symptom relief. In con-
trast to older studies that support the use of at least 
3000cGy, our experience with these cases and others 
suggests that 2000cGy-2400cGy is adequate10 .
CONCLUSION
In conclusion,we believe that the value of radiation 
therapy was investigated in these patients with chlo-
romas’ treated at the Radiotherapy Department of Ar-
istotelian University AHEPA Hospital. Such isolated 
recurrences may benefit from radiation therapy (low 
doses). This challenges the belief that chloromas al-
ways precede systemic relapse and suggests an evolv-
ing role for radiation therapy in the management of 
chloromas beyond palliation. Further,more compre-
hensive studies of chloromas are warranted to deter-
mine optimal management.
Figure 3. Reduction of chloroma after irradiation.
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ΠΕΡΙΛΗΨΗ: Το χλώρωμα (μυελοειδές σάρκωμα) είναι μια σπάνια εξωμυελική εκδήλωση αιματολογικής κακοήθειας 
περισσότερο συχνή στην οξεία μυελογενή λευχαιμία (ΟΜΛ). Μπορεί να εμφανιστεί σε σχέση  με τη μυελογενή λευχαιμία, 
μυελουπερπλαστικά σύνδρομα και διαταραχές, και μυελοδυσπλασία. Το μυελογενές σάρκωμα έχει διάφορες μορφές εκδή-
λωσης και μπορεί να προσβάλλει κάθε όργανο στο ανθρώπινο σώμα.
Λέξεις Κλειδιά: Χλώρωμα, Μυελοειδές σάρκωμα, Οξεία μυελογενής λευχαιμία, Ακτινοθεραπεία.
Ο θεραπευτικός ρόλος της ακτινοθεραπείας στο χλώρωμα:  
Αναφορά δυο περιπτώσεων και ανασκόπηση της βιβλιογραφίας.
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